NCT00614471View on ClinicalTrials.gov

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B.

PHASE4CompletedINTERVENTIONAL

Enrollment

219

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions

Hepatitis B, Chronic

Interventions

DRUG

Entecavir

0.5mg po daily for 24 weeks

DRUG

Entecavir

0.5mg po daily from week 13 to week 36

DRUG

peginterferon alfa-2a [Pegasys]

180 micrograms sc/week for 48 weeks

DRUG

peginterferon alfa-2a [Pegasys]

180 micrograms sc/week from week 21 to week 68

Trial Locations (8)

100011

Beijing

200021

Shanghai

200025

Shanghai

200235

Shanghai

310003

Hangzhou

450052

Zhengzhou

710038

Xi'an

Unknown

Hong Kong

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT00614471 - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B. | Biotech Hunter | Biotech Hunter